← Leaderboards
Naveen Luke Pereira
Mayo Clinic Rochester
$3,923,286
Attributed
$7,409,926
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2016–19$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
Funding mix
By agency
NIH$7,409,926 · 2
By mechanism
U01$6,973,280 · 1
R21$436,646 · 1
Top collaborators
- Michael E Farkouh4 shared
- Jeffrey E Olgin1 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Sasantha Jeson Sangaralingham$3,919,348
- Adam L Boxer$75,127,044
- Siobhan Malany$5,060,787
- Alexander Egbe$8,108,397
- Thomas Patrick Olson$5,622,167
Others in their field
Top investigators on “Enrollment”
- Jeffrey P Krischer · University Of South Florida$370,021,822
- Lawrence Corey · Fred Hutchinson Cancer Center$329,293,433
- David R. Weir · University Of Michigan At Ann Arbor$265,368,888
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$231,949,330
- James Dennis Neaton · Northwestern University$218,104,551
- George R Seage · Abt Associates, Inc.$205,403,788
Research focus
EnrollmentResponsePublic Health RelevancePatient RightsBasePharmaceutical PreparationsEnzymesPrevalenceClinicCessation Of LifeClinical PracticeAsiansAspirinAlternative TherapiesClopidogrelAngiographyAmerican Heart AssociationCaringCarrier StatusAllelesCanadaCardiac Catheterization ProceduresCardiologyBlood Platelets
Grant awards (7)
Clinical Implementation of Clopidogrel Pharmacogenetics: The TAILOR-PCI Trial - CCC - Lead Application$1,592,979
U01 · FY2019 · HL · contact PI
Clinical Implementation of Clopidogrel Pharmacogenetics: The TAILOR-PCI Trial - CCC - Lead Application$1,174,000
U01 · FY2018 · HL · contact PI
TAILOR PCI: Transitioning a Genotype Based Randomized Clinical Trial to a Registry Using Digital Solutions$876,953
U01 · FY2018 · HL · contact PI
Diagnostic and Therapeutic Approach to Heart Failure with Preserved Ejection Fraction Based on Circulating Neprilysin$237,896
R21 · FY2018 · AG · contact PI
Clinical Implementation of Clopidogrel Pharmacogenetics: The TAILOR-PCI Trial - CCC - Lead Application$1,613,336
U01 · FY2017 · HL · contact PI
Diagnostic and Therapeutic Approach to Heart Failure with Preserved Ejection Fraction Based on Circulating Neprilysin$198,750
R21 · FY2017 · AG · contact PI
Clinical Implementation of Clopidogrel Pharmacogenetics: The TAILOR-PCI Trial - CCC - Lead Application$1,716,012
U01 · FY2016 · HL · contact PI